NasdaqGM:HRMYPharmaceuticals
Harmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval
Harmony Biosciences Holdings recently reported Q4 2025 results showing net income of US$22.49 million and diluted EPS of US$0.38, alongside full-year 2025 net income of US$158.69 million and reiterated 2026 WAKIX net revenue guidance of US$1.00 billion to US$1.04 billion.
At the same time, FDA approval extending WAKIX to treat cataplexy in pediatric narcolepsy patients and progress securing its intellectual property framework could be important for Harmony’s long-term WAKIX franchise and...